Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeiGene, Ltd.    BGNE

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BeiGene Clinical Trial of Covid-19 Treatment Misses Co-Primary Efficacy Endpoints

04/08/2021 | 07:39am EDT

By Robb M. Stewart

BeiGene Ltd.'s trial of a potential treatment for patients in hospital with respiratory symptoms of Covid-19 failed to meet the two primary efficacy endpoints of the study.

The biotechnology company said its Phase 2 trial evaluating zanubrutinib in patients hospitalized with respiratory symptoms of Covid-19 and requiring supplemental oxygen without mechanical ventilation, didn't meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen as compared with a placebo.

There were no new or additional safety signals for zanubrutinib identified in the trial, it added.

The U.S. trial enrolled 67 patients with Covid-19 disease who either required supplemental oxygen or mechanical ventilation. It was designed to assess quickly whether treatment with zanubrutinib could help hospitalized patients with Covid-19-related pulmonary distress. Zanubrutinib is a small molecule inhibitor of Bruton's tyrosine kinase discovered by BeiGene scientists.

Following the update on the trial, BeiGene's American depositary receipts were down 0.9% in premarket trading after ending Wednesday at $321.60, a gain of almost 25% so far in 2021.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

04-08-21 0738ET

All news about BEIGENE, LTD.
02:35pBEIGENE  : Says Tislelizumab Trial Meets Primary Endpoint
MT
01:31pBEIGENE  : Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizu..
BU
03:37aBEIGENE  : Says Tislelizumab-Sitravatinib Combination Shows Preliminary Anti-Tum..
MT
04/11BEIGENE  : Voluntary announcement - update regarding recent business development..
PU
04/11BEIGENE  : Presents Clinical Data on Sitravatinib in Combination with Tislelizum..
BU
04/09BEIGENE  : Launches BRUKINSA (Zanubrutinib) in Canada for Patients with Waldenst..
AQ
04/08BEIGENE  : Overseas regulatory announcement - independent director compensation ..
PU
04/08BEIGENE, LTD.  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/08SECTOR UPDATE : Health Care Stocks Drift Away from Midday Highs
MT
04/08SECTOR UPDATE : Health Care Stocks Posting Modest Gains
MT
More news
Financials (USD)
Sales 2021 924 M - -
Net income 2021 -1 350 M - -
Net cash 2021 2 862 M - -
P/E ratio 2021 -23,0x
Yield 2021 -
Capitalization 28 269 M 28 269 M -
EV / Sales 2021 27,5x
EV / Sales 2022 17,2x
Nbr of Employees 5 300
Free-Float 69,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 346,39 $
Last Close Price 308,27 $
Spread / Highest target 65,2%
Spread / Average Target 12,4%
Spread / Lowest Target -48,7%
EPS Revisions
Managers and Directors
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Howard Liang Chief Financial & Strategy Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE, LTD.19.30%28 269
GILEAD SCIENCES, INC.11.76%81 977
VERTEX PHARMACEUTICALS-9.73%55 220
REGENERON PHARMACEUTICALS-1.64%49 486
WUXI APPTEC CO., LTD.3.61%45 479
BIONTECH SE49.83%29 499